Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Downstream targets of SSRI effect in treatment of Major Depressive Disorder
2019-002232-82Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of escitalopram in major depressive disorder (MDD), sponsored by Karolinska Institutet. Primary endpoint: Change in brain 5-HT1B receptor binding after SSRI treatment. Started Jun 2019; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-002232-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002232-82.